Hemodynamic data pattern in patients with acute pancreatitis.

H. Beger,H. Beger,R. Bittner,R. Bittner,M. Büchler,M. Büchler,W. Hess,W. Hess,Jürgen E. Schmitz,Jürgen E. Schmitz

DOI: https://doi.org/10.1016/0016-5085(86)90077-6

IF: 29.4

Gastroenterology

Abstract:

What problem does this paper attempt to address?

Mameliella atlantica sp. nov., a marine bacterium of the Roseobacter clade isolated from deep-sea sediment of the South Atlantic Ocean.

Hongxiu Xu,Lijing Jiang,Shaoneng Li,Xiang Zeng,Z. Shao

DOI: https://doi.org/10.1099/ijs.0.000248

IF: 2.689

2015-07-01

INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY

Abstract:A taxonomic study was carried out on strain L6M1-5(T), which was isolated from deep-sea sediment collected from the South Atlantic Ocean. The isolate was Gram-reaction-negative, oxidase-negative and catalase-weakly positive. Growth was observed in the presence of 0.5-15% (w/v) NaCl (optimum 3-5%), at 10-41 °C (optimum 28-30 °C), and pH 5.0-10.5 (optimum pH 7.0). The principal fatty acids were summed feature 8 (C18 : 1ω7c/ω6c) (84.2%), C18 : 0 (6.3%), C12 : 1 3-OH (3.2%) and C16 : 0 (2.7%). The polar lipid profile comprised phosphatidylethanolamine, phosphatidylglycerol, two unidentified aminolipids, two unknown phospholipids and one unknown lipid. Ubiquinone-10 was the major quinone. The G+C content of the genomic DNA was 66.0 mol %. Phylogenetic analyses based on 16S rRNA gene sequences showed that strain L6M1-5(T) belonged to the genus Mameliella and shared 95.8% sequence similarity with Mameliella alba JLT354-W(T). The combined genotypic and phenotypic data show that strain L6M1-5(T) represents a novel species of the genus Mameliella, for which the name Mameliella. atlantica sp. nov. is proposed. The type strain is L6M1-5(T) ( = MCCC 1A07531(T) = JCM 30230(T)).
Visual communication for the masses

J. Mohler

DOI: https://doi.org/10.1109/IV.2000.859744

2000-07-19

Abstract:Visual communication is vitally important to a variety of disciplines. Generally, information is communicated in a way that is deemed appropriate for the discipline, governed by established rules based on prior research. However when communicating to general audiences en masse, it is imperative that information be presented as simply as possible-the rules governing specialized scientific communication may or may not be applicable. In short, accessing information should be straightforward, allowing the users to efficiently gain the knowledge for which they are searching. The visual content that is presented should be clear, concise and accurate. With this in mind, this paper discusses issues related to delivering spatially-oriented data to the general populace. Communication through computer graphics should be for the masses as much as it is for individual disciplines. As such, the first half of this paper examines issues related to visual communication for the mass population, while the later half examines one such resource being used for visualization and communication at Purdue University.
CFH and CFHR structural variants in atypical Hemolytic Uremic Syndrome: Prevalence, genomic characterization and impact on outcome

Rossella Piras,Elisabetta Valoti,Marta Alberti,Elena Bresin,Caterina Mele,Matteo Breno,Lucia Liguori,Roberta Donadelli,Miriam Rigoldi,Ariela Benigni,Giuseppe Remuzzi,Marina Noris

DOI: https://doi.org/10.3389/fimmu.2022.1011580

2023-01-30

Abstract:Introduction: Atypical hemolytic uremic syndrome (aHUS) is a rare disease that manifests with microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure, and is associated with dysregulation of the alternative complement pathway. The chromosomal region including CFH and CFHR1-5 is rich in repeated sequences, favoring genomic rearrangements that have been reported in several patients with aHUS. However, there are limited data on the prevalence of uncommon CFH-CFHR genomic rearrangements in aHUS and their impact on disease onset and outcomes. Methods: In this study, we report the results of CFH-CFHR Copy Number Variation (CNV) analysis and the characterization of resulting structural variants (SVs) in a large cohort of patients, including 258 patients with primary aHUS and 92 with secondary forms. Results: We found uncommon SVs in 8% of patients with primary aHUS: 70% carried rearrangements involving CFH alone or CFH and CFHR (group A; n=14), while 30% exhibited rearrangements including only CFHRs (group B; n=6). In group A, 6 patients presented CFH::CFHR1 hybrid genes, 7 patients carried duplications in the CFH-CFHR region that resulted either in the substitution of the last CFHR1 exon(s) with those of CFH (CFHR1::CFH reverse hybrid gene) or in an internal CFH duplication. In group A, the large majority of aHUS acute episodes not treated with eculizumab (12/13) resulted in chronic ESRD; in contrast, anti-complement therapy induced remission in 4/4 acute episodes. aHUS relapse occurred in 6/7 grafts without eculizumab prophylaxis and in 0/3 grafts with eculizumab prophylaxis. In group B, 5 subjects had the CFHR31-5::CFHR410 hybrid gene and one had 4 copies of CFHR1 and CFHR4. Compared with group A, patients in group B exhibited a higher prevalence of additional complement abnormalities and earlier disease onset. However, 4/6 patients in this group underwent complete remission without eculizumab treatment. In secondary forms we identified uncommon SVs in 2 out of 92 patients: the CFHR31-5::CFHR410 hybrid and a new internal duplication of CFH. Discussion: In conclusion, these data highlight that uncommon CFH-CFHR SVs are frequent in primary aHUS and quite rare in secondary forms. Notably, genomic rearrangements involving the CFH are associated with a poor prognosis but carriers respond to anti-complement therapy.
Clinical and Genetic Characteristics of Atypical Hemolytic Uremic Syndrome in Children: A Chinese Cohort Study

Dan Wu,Jiahui Chen,Chen Ling,Zhi Chen,Jianfeng Fan,Qiang Sun,Qun Meng,Xiaorong Liu

DOI: https://doi.org/10.1159/000513009

Nephron

Abstract:Background: Atypical hemolytic uremic syndrome (aHUS) is a rare but critical illness. To this date, few studies have reported on the disease in Chinese children. Methods: We studied a Chinese pediatric cohort to delineate the clinical characteristics, genotypes, and prognosis. Ninety-one patients with aHUS were enrolled in this study. Results: Fifty-nine children (64.8%) had anti-complement-factor-H autoantibody-associated aHUS (anti-CFH aHUS). Of these children, 21 (46.7%) had complement factor-H-related protein 1 (CFHR1) homozygous deletion, and most patients with CFHR1 homozygous deletion also had complement factor-H-related protein 3 (CFHR3) homozygous deletions (76.2%). Using gene sequencing of 15 candidate genes, we identified 14 genetic variants in 46 aHUS patients, including 5 pathogenic or like pathogenic variants and 9 variants of uncertain significance. The average follow-up time was 46.1 ± 28 months. Among patients with anti-CFH aHUS, there was a correlation between CFHR1 homozygous deletion and patients with persistent proteinuria (odds ratio [OR] 6.954, 95% confidence interval [CI] 1.033-46.821, p = 0.046). As of the last follow-up, ESRD or deaths occurred in 3.6% of the children with anti-CFH aHUS and 26.7% of children with aHUS who were negative for anti-CFH. Conclusions: Anti-complement-factor-H antibody positivity is the main cause of morbidity in Chinese children with aHUS. There may be a correlation between CFHR1 homozygous deletion and persistent proteinuria. Comprehensive assessment of anti-CFH antibodies and genetic variants is essential for the management of aHUS children.
GANCICLOVIR THERAPY OF SEVERE CYTOMEGALOVIRUS INFECTIONS IN SOLID‐ORGAN TRANSPLANT RECIPIENTS

M. A. Harbison,P. D. De Girolami,R. Jenkins,S. Hammer

DOI: https://doi.org/10.1097/00007890-198807000-00015

1988-07-01

Transplantation

Abstract:The clinical and virologic efficacy of ganciclovir (9-[1,3-dihydroxy-2-propoxymethyl]guanine) in the treatment of severe CMV infections in solid organ transplant recipients was investigated. Twelve patients (9 liver and 3 kidney transplant recipients) with CMV retinitis, esophagitis, hepatitis, or pneumonia received ganciclovir at a dose of 0.75–7.5 mg/kg/day for 10–30 days (mean duration 17 days). Clinical stabilization or improvement occurred in 8 patients (67%). Serial liver biopsies in 6 liver allograft recipients with CMV hepatitis demonstrated substantial histologic improvement on treatment. Of 6 patients with CMV pneumonia, 4 (67%) recovered and survived. Cultures of blood and other sites became negative in 9 patients (75%). Three patients (25%) had recurrent viral shedding after treatment, but none of these relapsed with invasive infections. Mild neutropenia was the only side effect encountered but was frequent (67%). The overall survival rate was 50%. Ganciclovir is effective in reducing CMV shedding in solid organ transplant recipients and is well tolerated. Our experience suggests a clinical benefit as well in patients with severe, invasive CMV disease. Relapse, in contrast to patients with the acquired immunodeficiency syndrome, is infrequent.
Immunological features and functional analysis of anti-CFH autoantibodies in patients with atypical hemolytic uremic syndrome

Wei-yi Guo,Di Song,Xiao-rong Liu,Zhi Chen,Hui-jie Xiao,Jie Ding,Shu-zhen Sun,Hong-yan Liu,Su-xia Wang,Feng Yu,Ming-hui Zhao,

DOI: https://doi.org/10.1007/s00467-018-4074-4

2018-10-12

Pediatric Nephrology

Abstract:ObjectiveAtypical hemolytic uremic syndrome (aHUS) is associated with defective complement regulation. Anti-complement factor H (CFH) antibodies were thought to participate in the pathogenesis of aHUS. The aim of this study was to address the functions and properties of CFH autoantibodies in a Chinese Han cohort of aHUS patients.MethodsThirty-six anti-CFH antibody-positive aHUS patients at the acute phase of the disease were involved in this study. Clinical data of the patients were collected. Anti-CFH immunoglobulin G (IgG) subclasses and antibody isotypes were detected by ELISA. Epitope mapping was performed using recombinant CFH fragments (SCRs 1–4, SCR 7, SCRs 11–14, and SCRs 19–20). Purified IgG from plasma from seven patients were used for functional analyses.ResultsAll patients presented with the classic triad of HUS. The anti-CFH autoantibodies mostly bound to the SCRs 19–20 domains of CFH but not the SCRs 1–4 domains. CFI cofactor activity was not disturbed by the anti-CFH antibody in any of the seven patients. Purified IgG interfered with the binding of CFH to C3b and CFH-mediated sheep erythrocyte protection in all seven patients. IgG from 4/5 (80%) patients tested inhibited the binding of CFH to glomerular endothelial cells.ConclusionsOur study suggests that the properties of CFH antibodies from patients with aHUS, including the recognition of SCRs and IgG subclasses, can influence and impair the biological role of CFH and therefore contribute to aHUS susceptibility.

pediatrics,urology & nephrology
Atypical Hemolytic Uremic Syndrome-Associated FHR1 Isoform FHR1*B Enhances Complement Activation and Inflammation

Yuqi Kang,Boyang Xu,Yujing Du,Weiyi Guo,Li Zhu,Hong Zhang

DOI: https://doi.org/10.3389/fimmu.2022.755694

IF: 7.3

2022-01-01

Frontiers in Immunology

Abstract:Atypical hemolytic uremic syndrome (aHUS) is a rare but severe type of thrombotic microangiopathy that is triggered by the abnormal activation of the alternative complement pathway. Previous studies have reported that three completely linked coding variants of CFHR1 form two haplotypes, namely, CFHR1 *A (c.469C, c.475C, c.523G) and CFHR1 *B (c.469T, c.475G, c.523C). CFHR1 *B is associated with susceptibility to aHUS. To explore the genetic mechanism by which CFHR1 isoforms contribute to aHUS, we compared the structures of FHR1*A and FHR1*B by homology modeling and found differences in the angles between SCR3 and SCR4-SCR5, as FHR1*B had a larger angle than FHR1*A. Then, we expressed FHR1*A and FHR1*B recombinant proteins and compared their functions in complement system regulation and inflammation. We found that FHR1*B presented a significantly higher capacity for binding C3b and necrotic cells than FHR1*A. In a cofactor assay, the FHR-1*B showed stronger influence on FH mediated cofactor function than the FHR-1*A, resulted in fewer C3b cleavage products. In the C3 convertase assays, FHR1*B showed more powerful effect compared with FHR1*A regarding to de-regulate FH function of inhibition the assembling of C3bBb. Additionally, we also found that FHR1*B triggered monocytes to secrete higher levels of IL-1β and IL-6 than FHR1*A. In the present study, we showed that variants of CFHR1 might differently affect complement activation and sterile inflammation. Our findings provide a possible mechanism underlying the predisposition to aHUS caused by CFHR1 isoform CFHR1 *B.
Anti-factor B antibodies in atypical hemolytic uremic syndrome

Priyanka Khandelwal,Shreesha Nambiar,Rahul Saini,Savita Saini,Poonam Coshic,Aditi Sinha,Pankaj Hari,Jayanth Kumar Palanichamy,Arvind Bagga

DOI: https://doi.org/10.1007/s00467-024-06284-x

2024-01-22

Pediatric Nephrology

Abstract:BackgroundThe etiology of atypical hemolytic uremic syndrome (aHUS) is unknown in 30–40% of patients. Anti-factor B (FB) antibodies are reported in C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN), though not in aHUS.MethodsWe screened patients < 18-year-old from cohorts of aHUS and C3G/idiopathic IC-MPGN. Anti-FB IgG antibodies were measured by ELISA and confirmed by Western blot. Normative levels were based on antibody levels in 103 healthy blood donors.ResultsPrevalence of anti-FB antibodies was 9.7% (95% CI 6.1–14.5%; n = 21) in 216 patients with aHUS, including 11.5% (95% CI 6.4–18.5%; n = 14) in anti-FH associated aHUS and 11.8% (95% CI 4.4–23.9%; n = 6) in patients without a definitive genetic or autoimmune etiology. Patients with significant genetic variants did not show anti-FB antibodies. In patients with concomitant anti-FB and anti-FH antibodies, median anti-FH titers were higher (11,312 AU/mL vs. 4920 AU/mL; P = 0.04). Anti-FB antibody titer correlated with disease severity (hemoglobin and platelets; P < 0.05), declined following plasma exchange and increased during relapse. While 4/64 patients with C3G (6.3%) and 1/17 with IC-MPGN showed anti-FB antibodies, titers were higher in aHUS (544.8 AU/mL vs. 1028.8 AU/mL; P = 0.003).ConclusionAnti-FB antibodies are present in 6–10% of patients with aHUS and C3G/IC-MPGN, with higher titers in the former. The diagnostic and therapeutic implication of anti-FB antibodies in aHUS needs confirmation and further studies. The study shows propensity for autoantibody generation and co-existence of multiple risk factors for aHUS in Indian children.Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information

pediatrics,urology & nephrology
Genetics of Atypical Hemolytic Uremic Syndrome (aHUS)

Santiago Rodríguez de Córdoba,Marta Subías Hidalgo,Sheila Pinto,Agustín Tortajada,Marta Hidalgo

DOI: https://doi.org/10.1055/s-0034-1375296

2014-05-05

Seminars in Thrombosis and Hemostasis

Abstract:Hemolytic uremic syndrome (HUS) is a rare, life-threatening disease characterized by thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure. The atypical form of HUS (aHUS), representing 5 to 10% of cases, lacks the association with infection by Shiga toxin producing Escherichia coli strains that characterizes the commonest clinical presentation of HUS. In the majority of aHUS cases, the disease results from the complement-mediated damage to the microvascular endothelium because of inherited defects in complement genes or autoantibodies against complement regulatory proteins. Incomplete penetrance of aHUS in carriers of mutations is common to all aHUS-associated complement genes and it is now established that the overall genetic predisposition to aHUS of an individual results from the combination of different inherited factors. Moreover, the patient's genotype influences the clinical evolution, the response to plasma therapies, and the recurrence after transplantation. Here, we describe the genetic component of aHUS, the lessons that we have learned from the functional characterization of the aHUS-associated mutations, and the benefits of a comprehensive genetic analysis of the patients.

peripheral vascular disease,hematology
Role of Mastoid Pneumatization in Temporal Bone Fractures

A. Ilea,A. Butnaru,S. Sfrangeu,Mihaela Hedesiu,Cristian Dudescu,P. Berce,H. Chezan,L. Hurubeanu,V. E. Trombiţaş,R. Câmpian,S. Albu

DOI: https://doi.org/10.3174/ajnr.A3887

IF: 4.9661

2014-07-01

American Journal of Neuroradiology

Abstract:BACKGROUND AND PURPOSE: The mastoid portion of the temporal bone has multiple functional roles in the organism, including regulation of pressure in the middle ear and protection of the inner ear. We investigated whether mastoid pneumatization plays a role in the protection of vital structures in the temporal bone during direct lateral trauma. MATERIAL AND METHODS: The study was performed on 20 human temporal bones isolated from cadavers. In the study group formed by 10 temporal bone samples, mastoid cells were removed and the resulting neocavities were filled. The mastoids were maintained intact in the control group. All samples were impacted at the same speed and kinetic energy. The resultant temporal bone fractures were evaluated by CT. RESULTS: Temporal squama fractures were 2.88 times more frequent, and mastoid fractures were 2.76 times more frequent in the study group. Facial nerve canal fractures were 6 times more frequent in the study group and involved all the segments of the facial nerve. Carotid canal fractures and jugular foramen fractures were 2.33 and 2.5 times, respectively, more frequent in the study group. CONCLUSIONS: The mastoid portion of the temporal bone plays a role in the absorption and dispersion of kinetic energy during direct lateral trauma to the temporal bone, reducing the incidence of fracture in the setting of direct trauma.
The clinical and laboratory features of Chinese Han anti-factor H autoantibody-associated hemolytic uremic syndrome

Di Song,Xiao-rong Liu,Zhi Chen,Hui-jie Xiao,Jie Ding,Shu-zhen Sun,Hong-yan Liu,Wei-yi Guo,Su-xia Wang,Feng Yu,Ming-hui Zhao,On Behalf of the Chinese Renal–TMA Network Institutes,

DOI: https://doi.org/10.1007/s00467-016-3562-7

2016-12-29

Pediatric Nephrology

Abstract:BackgroundAnti-complement factor H (CFH) autoantibody-associated hemolytic uremic syndrome (HUS) is a severe sub-type of HUS.MethodsWe assessed the clinical and renal pathological features, circulating complement levels, and genetic background of Chinese pediatric patients with this sub-type of HUS. Thirty-three consecutive patients with acute kidney injury who tested positive for serum anti-CFH autoantibodies were enrolled in this study.ResultsAll of the eight patients who underwent renal biopsies presented with changes typical of thrombotic microangiopathy, especially changes in chronic characteristics. Compared to patients in remission and normal control subjects, patients with acute disease had significantly lower plasma CFH levels and significantly higher plasma complement 3a (C3a), C5a, and terminal complement complex (SC5b-9) levels. The CFH–anti-CFH immunoglobin G (IgG) circulating immunocomplex (CFH-CIC) titers were more closely correlated with CFH plasma levels than anti-CFH IgG levels. Of the 22 patients, four (18%) were homozygous for CFHR3–1Δ and ten were heterozygous for CFHR1 or CFHR3 deletions. Most patients responded well to a combination of plasma and immunosuppressive therapies, with a remission rate of 87%. At the end of the follow-up, nine patients reached the combined end-points, including two with end-stage renal disease and seven with relapses.ConclusionPlasma C3a, C5a, and SC5b-9 levels predicted disease activity in anti-CFH autoantibody-associated HUS patients enrolled in this study. These patients responded well to plasma therapy combined with immunosuppression.

pediatrics,urology & nephrology
Complement Factor I Variants in Complement-Mediated Renal Diseases

Yuzhou Zhang,Nicolo Ghiringhelli Borsa,Dingwu Shao,Renee X. Goodfellow,Hannah C. Dunlop,Stephen A. Presti,Nicole C. Meyer,Sarah M. Roberts,Michael B. Jones,Gabriella R. Pitcher,Amanda O. Taylor,Carla M. Nester,Richard J. H. Smith

DOI: https://doi.org/10.3389/fimmu.2022.866330

IF: 7.3

2022-05-11

Frontiers in Immunology

Abstract:C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS) are two rare diseases caused by dysregulated activity of the alternative pathway of complement secondary to the presence of genetic and/or acquired factors. Complement factor I (FI) is a serine protease that downregulates complement activity in the fluid phase and/or on cell surfaces in conjunction with one of its cofactors, factor H (FH), complement receptor 1 (CR1/CD35), C4 binding protein (C4BP) or membrane cofactor protein (MCP/CD46). Because altered FI activity is causally related to the pathogenesis of C3G and aHUS, we sought to test functional activity of select CFI missense variants in these two patient cohorts. We identified 65 patients (16, C3G; 48, aHUS; 1 with both) with at least one rare variant in CFI (defined as a MAF < 0.1%). Eight C3G and eleven aHUS patients also carried rare variants in either another complement gene, ADAMTS13 or THBD . We performed comprehensive complement analyses including biomarker profiling, pathway activity and autoantibody testing, and developed a novel FI functional assay, which we completed on 40 patients. Seventy-eight percent of rare CFI variants (31/40) were associated with FI protein levels below the 25 th percentile; in 22 cases, FI levels were below the lower limit of normal (type 1 variants). Of the remaining nine variants, which associated with normal FI levels, two variants reduced FI activity (type 2 variants). No patients carried currently known autoantibodies (including FH autoantibodies and nephritic factors). We noted that while rare variants in CFI predispose to complement-mediated diseases, phenotypes are strongly contingent on the associated genetic background. As a general rule, in isolation, a rare CFI variant most frequently leads to aHUS, with the co-inheritance of a CD46 loss-of-function variant driving the onset of aHUS to the younger age group. In comparison, co-inheritance of a gain-of-function variant in C3 alters the phenotype to C3G. Defects in CFH (variants or fusion genes) are seen with both C3G and aHUS. This variability underscores the complexity and multifactorial nature of these two complement-mediated renal diseases.

immunology
Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy

Amy J Osborne,Matteo Breno,Nicolo Ghiringhelli Borsa,Fengxiao Bu,Véronique Frémeaux-Bacchi,Daniel P Gale,Lambertus P van den Heuvel,David Kavanagh,Marina Noris,Sheila Pinto,Pavithra M Rallapalli,Giuseppe Remuzzi,Santiago Rodríguez de Cordoba,Angela Ruiz,Richard J H Smith,Paula Vieira-Martins,Elena Volokhina,Valerie Wilson,Timothy H J Goodship,Stephen J Perkins,Amy J. Osborne,Daniel P. Gale,Lambertus P. van den Heuvel,Pavithra M. Rallapalli,Richard J. H. Smith,Timothy H. J. Goodship,Stephen J. Perkins

DOI: https://doi.org/10.4049/jimmunol.1701695

2018-03-02

The Journal of Immunology

Abstract:Atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) are associated with dysregulation and overactivation of the complement alternative pathway. Typically, gene analysis for aHUS and C3G is undertaken in small patient numbers, yet it is unclear which genes most frequently predispose to aHUS or C3G. Accordingly, we performed a six-center analysis of 610 rare genetic variants in 13 mostly complement genes (CFH, CFI, CD46, C3, CFB, CFHR1, CFHR3, CFHR4, CFHR5, CFP, PLG, DGKE, and THBD) from >3500 patients with aHUS and C3G. We report 371 novel rare variants (RVs) for aHUS and 82 for C3G. Our new interactive Database of Complement Gene Variants was used to extract allele frequency data for these 13 genes using the Exome Aggregation Consortium server as the reference genome. For aHUS, significantly more protein-altering rare variation was found in five genes CFH, CFI, CD46, C3, and DGKE than in the Exome Aggregation Consortium (allele frequency < 0.01%), thus correlating these with aHUS. For C3G, an association was only found for RVs in C3 and the N-terminal C3b-binding or C-terminal nonsurface-associated regions of CFH In conclusion, the RV analyses showed nonrandom distributions over the affected proteins, and different distributions were observed between aHUS and C3G that clarify their phenotypes.
Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome

Tara K. Maga,Carla J. Nishimura,Amy E. Weaver,Kathy L. Frees,Richard J.H. Smith

DOI: https://doi.org/10.1002/humu.21256

2010-04-13

Human Mutation

Abstract:Atypical hemolytic uremic syndrome (aHUS) is characterized by acute renal failure, thrombocytopenia and microangiopathic hemolytic anemia, and occurs with an estimated incidence in the USA of 2 per 1,000,000. Disease pathogenesis is related to dysregulation of the alternative pathway (AP) of the complement cascade at the level of the cell membrane secondary to mutations in a number of complement genes including complement factor H (CFH), complement factor H-related 5 (CFHR5), complement factor I (CFI), CD46 (MCP), complement factor B (CFB), complement component 3 (C3) and thrombomodulin (THBD). Since aHUS is rare, mutation rate data in large patient cohorts are scarce. Here we present the first cohort of American patients in whom mutation screening was completed on all genes currently implicated in aHUS. In addition to identifying a number of novel variants, we provide information on the relative frequency of mutations in these genes in an American aHUS population. Twelve percent (12%) of patients carrying disease-associated genetic variants segregated mutations in more than one gene mandating comprehensive genetic testing in the diagnosis and management of these patients.

genetics & heredity
Case report: A family of atypical hemolytic uremic syndrome involving a CFH::CFHR1 fusion gene and CFHR3-1-4-2 gene duplication

Yuko Tasaki,Hiroshi Tsujimoto,Tadafumi Yokoyama,Naotoshi Sugimoto,Shinji Kitajima,Hiroshi Fujii,Yoshihiko Hidaka,Noritoshi Kato,Shoichi Maruyama,Norimitsu Inoue,Taizo Wada

DOI: https://doi.org/10.3389/fimmu.2024.1360855

IF: 7.3

2024-03-08

Frontiers in Immunology

Abstract:Mutations in the complement factor H ( CFH ) gene are associated with complement dysregulation and the development of atypical hemolytic uremic syndrome (aHUS). Several fusion genes that result from genomic structural variation in the CFH and complement factor H-related ( CFHR ) gene regions have been identified in aHUS. However, one allele has both CFHR gene duplication and CFH::CFHR1 fusion gene have not been reported. An 8-month-old girl (proband) presented with aHUS and was treated with ravulizumab. Her paternal grandfather developed aHUS previously and her paternal great grandmother presented with anti-neutrophil cytoplasmic antibody-associated vasculitis and thrombotic microangiopathy (TMA). However, the proband's parents have no history of TMA. A genetic analysis revealed the presence of CFH::CFHR1 fusion gene and a CFHR3-1-4-2 gene duplication in the patient, her father, and her paternal grandfather. Although several fusion genes resulting from structural variations of the CFH–CFHR genes region have been identified, this is the first report of the combination of a CFH::CFHR1 fusion gene with CFHR gene duplication. Because the CFH–CFHR region is highly homologous, we hypothesized that CFHR gene duplication occurred. These findings indicate a novel pathogenic genomic structural variation associated with the development of aHUS.

immunology
Evaluation of complement regulatory components in patients with atypical hemolytic uremic syndrome

Hosseini Soudabeh,Kalantar Ebrahim,Hooman Nakisa,Dorgalaleh Akbar,Hosseini Shamsabadi Rozita,Taregh Bamedi

DOI: https://doi.org/10.5114/ceji.2014.42127

2014-01-01

Central European Journal of Immunology

Abstract:BACKGROUND: Atypical hemolytic uremic syndrome (aHUS), a rare disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure, is associated with mutations and polymorphisms in various components and regulators of the complement alternative pathway (AP), including factor H, factor I, membrane cofactor protein (MCP or CD46) and factor B. This impaired regulation of the alternative pathway leads to a procoagulant state with microthrombi formation in the renal vasculature, which influences disease onset and progression.AIM OF THE STUDY: To evaluate the role of complement regulatory factors in occurrence of aHUS; we also included evaluation of ADAMTS13 activity and autoantibody against ADAMTS13 in order to exclude thrombotic thrombocytopenic purpura (TTP) cases, which might have overlapping clinical and laboratory findings.MATERIAL AND METHODS: This study was conducted on 273 individuals with aHUS. Diagnosis was based on clinical manifestations, kidney function tests, red blood cell count, morphology and reticulocyte count. Then, the ADAMTS 13 autoantibody and activity and also complement factor B, complement factor H (CFH) and complement factor-I (CIF) were analyzed. Finally, the statistical analysis was performed by SPSS software.RESULTS: The mean age of our patients was 27.3 years, 55% were female and 45% were male. The mean levels of urea and creatinine concentration were 92.9 mg/dl and 5.1 mg/dl, respectively. The mean levels of RBC count, Hb and HCT in these patients were lower than normal but the mean percentage of reticulocyte count was higher than normal (2.5%). The assessment of complement regulatory factors revealed that the B and H factors levels were normal except in two cases but the level of factor I was higher than normal.CONCLUSIONS: According to the results of this study, it seems that up regulation of factor I had a significant role in occurrence of aHUS in our study group.

immunology
Comprehensive Analysis of Complement Genes in Patients with Atypical Hemolytic Uremic Syndrome

Tao Zhang,Jianping Lu,Shaoshan Liang,Dachen Chen,Haitao Zhang,Caihong Zeng,Zhihong Liu,Huimei Chen

DOI: https://doi.org/10.1159/000445127

2016-01-01

American Journal of Nephrology

Abstract:BACKGROUND:Genetic defects in complement proteins reportedly contribute to the atypical hemolytic uremic syndrome (aHUS). Numerous genetic studies have been published in recent years, but limited data have been gathered from Asian countries.METHODS:Genetic variants of 11 complement genes were analyzed in 23 Chinese patients with aHUS by high-throughput sequencing. The genotype-phenotype relationship in the Han population was evaluated and compared with the relationship that existed in other ethnicities.RESULTS:We identified 20 causative mutations in complement genes, including 19 missense mutations and 1 splicing mutation. Six previously reported mutations, 6 mutations detected for the first time, and 8 rare polymorphisms were noted. Twelve out of 23 patients harbored complement mutations. Among the patients, one was a homozygote (Arg142Cys in CFHR3), and 4 carried combined mutations. Chinese patients have a similar prevalence of complement mutations as European, Japanese, and American patients. Complement factor H (CFH) mutations were common in aHUS in different ethnicities, but Chinese patients exhibited a higher percentage of complement factor B mutations than were found in European patients and a lower percentage of component 3 (C3) mutations than in Japanese patients. Compared with non-carriers, the aHUS patients carrying mutations had reduced C3 levels. In particular, patients with CFH mutations had a worse renal function than those with membrane cofactor protein mutations, a higher level of serum creatinine at the disease onset and a higher percentage of renal insufficiency during follow-up.CONCLUSIONS:Because complement genetic dysfunction has clinical significance in aHUS, a comprehensive assessment of variants is necessary for the proper management of aHUS patients in China.
A haplotype in CFH family genes confers high risk of rare glomerular nephropathies

Yin Ding,Weiwei Zhao,Tao Zhang,Hao Qiang,Jianping Lu,Xin Su,Shuzhen Wen,Feng Xu,Mingchao Zhang,Haitao Zhang,Caihong Zeng,Zhihong Liu,Huimei Chen

DOI: https://doi.org/10.1038/s41598-017-05173-8

IF: 4.6

2017-01-01

Scientific Reports

Abstract:Despite distinct renal lesions, a series of rare glomerular nephropathies are reportedly mediated by complement overactivation. Genetic variations in complement genes contribute to disease risk, but the relationship of genotype to phenotype has not been straightforward. Here, we screened 11 complement genes from 91 patients with atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy (C3G) and membranoproliferative glomerulonephritis type I (MPGN I), and identified the concomitant presence of three missense variations located within the human complement Factor H (CFH) gene cluster. The three variations, rs55807605, rs61737525 and rs57960694, have strong linkage disequilibrium; subsequent haplotype analysis indicated that ATA increased the susceptibility of these renal diseases. In silico analysis, the CFHR3 rs61737525-T risk allele altered the physical and structural properties and generated a reduction in binding affinity of the CFHR3/C3b complex. Surface plasmon resonance (SPR) binding analysis further demonstrated the substitution induced a decrease of two orders of magnitude in C3b-binding properties, with a declined cofactor activity in fluid phase. These data suggest that the haplotype carrying the causative allele behaves as a partial C3 convertase deficiency, predisposing individuals to diverse pathologic lesions underlying complement overactivation. Such genotype-phenotype discrepancies allow better understanding about these nephropathies mediated by genetic complement disorders.
Stability of biological father presence as a proxy for family stability: cross-racial associations with the longitudinal development of emotion regulation in toddlerhood.

E. Bocknek,H. Brophy-Herb,H. Fitzgerald,R. Schiffman,Cheri A. Vogel

DOI: https://doi.org/10.1002/imhj.21454

2014-07-01

Infant Mental Health Journal

Abstract:The current study, utilizing data from the National Early Head Start Research and Evaluation Project (Love et al., 2005) explored the relationship between biological father presence and emotion regulation over toddlerhood among children from low-income families. Conceptualizing biological father presence as a proxy for family role development, results are interpreted from a role development theoretical perspective. The latent growth curve model was compared based on child ethnoracial status (African American, Caucasian, Hispanic) and child gender. Consistent biological father presence was associated with toddlers' regulatory development across toddlerhood, and this relationship was most robust among Caucasian toddlers as compared to African American toddlers. Findings for Hispanic toddlers were not significantly different from those of Caucasian or African American families. Results bolster the literature on father presence and child outcomes. Analyses address consistency in father presence as a proxy for coherent role development and define a link between consistent father presence and children's regulatory development, demonstrating ethnoracial differences which are likely attributed to the social construction of family roles.
Clinical Characteristics and Outcome of Canadian Patients Diagnosed With Atypical Hemolytic Uremic Syndrome

Anne-Laure Lapeyraque,Martin Bitzan,Imad Al-Dakkak,Mira Francis,Shih-Han S Huang,Roger Kaprielian,Loree Larratt,Katerina Pavenski,Christine Ribic,Axel Tosikyan,Christoph Licht,David Philibert

DOI: https://doi.org/10.1177/2054358119897229

2020-01-24

Abstract:Background: Atypical hemolytic uremic syndrome (aHUS) is an extremely rare, heterogeneous disease of uncontrolled activation of the alternative complement pathway that is difficult to diagnose. We have evaluated the Canadian patients enrolled in the Global aHUS Registry to provide a Canadian perspective regarding the diagnosis and management of aHUS and the specific challenges faced. Objective: To evaluate Canadian patients enrolled in the Global aHUS Registry to provide a Canadian perspective regarding the diagnosis and management of aHUS and the specific challenges faced. Methods: The Global aHUS Registry is an observational, noninterventional, multicenter study that has prospectively and retrospectively collected data from patients of all ages with an investigator-made clinical diagnosis of aHUS, irrespective of treatment. Patients of all ages with a clinical diagnosis of aHUS were eligible and invited for enrollment, and those with evidence of Shiga toxin-producing Escherichia coli infection, or with ADAMTS13 activity ≤10%, or a subsequent diagnosis of thrombotic thrombocytopenic purpura were excluded. Data were collected at enrollment and every 6 months thereafter and were analyzed descriptively for categorical and continuous variables. End-stage renal disease (ESRD)-free survival was evaluated using Kaplan-Meier estimates, and ESRD-associated risk factors of interest were assessed using Cox proportional hazards regression models. Patients were censored at start of eculizumab for any outcome measures. Results: A total of 37 Canadian patients were enrolled (15 pediatric and 22 adult patients) between February 2014 and May 2017; the median age at initial aHUS presentation was 25.9 (interquartile range = 6.7-51.7) years; 62.2% were female and 94.6% had no family history of aHUS. Over three-quarters of patients (78.4%) had no conclusive genetic or anti-complement factor H (CFH) antibody information available, and most patients (94%) had no reported precipitating factors prior to aHUS diagnosis. Nine patients (8 adults and 1 child) experienced ESRD prior to the study. After initial presentation, there appears to be a trend that children are less likely to experience ESRD than adults, with 5-year ESRD-free survival of 93 and 56% (P = .05) in children and adults, respectively. Enrolling physicians reported renal manifestations in all patients at initial presentation, and 68.4% of patients during the chronic phase (study entry ≥6 months after initial presentation). Likewise, extrarenal manifestations also occurred in more patients during the initial presenting phase than the chronic phase, particularly for gastrointestinal (61.1% vs 15.8%) and central nervous system sites (38.9% vs 5.3%). Fewer children than adults experienced gastrointestinal manifestations (50.0% vs 70.0%), but more children than adults experienced pulmonary manifestations (37.5% vs 10.0%). Conclusions: This evaluation provides insight into the diagnosis and management of aHUS in Canadian patients and the challenges faced. More genetic or anti-CFH antibody testing is needed to improve the diagnosis of aHUS, and the management of children and adults needs to consider several factors such as the risk of progression to ESRD is based on age (more likely in adults), and that the location of extrarenal manifestations differs in children and adults.

Hemodynamic data pattern in patients with acute pancreatitis.

Mameliella atlantica sp. nov., a marine bacterium of the Roseobacter clade isolated from deep-sea sediment of the South Atlantic Ocean.

Visual communication for the masses

CFH and CFHR structural variants in atypical Hemolytic Uremic Syndrome: Prevalence, genomic characterization and impact on outcome

Clinical and Genetic Characteristics of Atypical Hemolytic Uremic Syndrome in Children: A Chinese Cohort Study

GANCICLOVIR THERAPY OF SEVERE CYTOMEGALOVIRUS INFECTIONS IN SOLID‐ORGAN TRANSPLANT RECIPIENTS

Immunological features and functional analysis of anti-CFH autoantibodies in patients with atypical hemolytic uremic syndrome

Atypical Hemolytic Uremic Syndrome-Associated FHR1 Isoform FHR1*B Enhances Complement Activation and Inflammation

Anti-factor B antibodies in atypical hemolytic uremic syndrome

Genetics of Atypical Hemolytic Uremic Syndrome (aHUS)

Role of Mastoid Pneumatization in Temporal Bone Fractures

The clinical and laboratory features of Chinese Han anti-factor H autoantibody-associated hemolytic uremic syndrome

Complement Factor I Variants in Complement-Mediated Renal Diseases

Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy

Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome

Case report: A family of atypical hemolytic uremic syndrome involving a CFH::CFHR1 fusion gene and CFHR3-1-4-2 gene duplication

Evaluation of complement regulatory components in patients with atypical hemolytic uremic syndrome

Comprehensive Analysis of Complement Genes in Patients with Atypical Hemolytic Uremic Syndrome

A haplotype in CFH family genes confers high risk of rare glomerular nephropathies

Stability of biological father presence as a proxy for family stability: cross-racial associations with the longitudinal development of emotion regulation in toddlerhood.

Clinical Characteristics and Outcome of Canadian Patients Diagnosed With Atypical Hemolytic Uremic Syndrome